FGF21 and Hepatic steatosis: Fibroblast growth factor-21 levels were significantly higher in MASLD groups, with the highest levels observed in obese MASLD patients, aligning with its role as a hepatokine secreted in response to metabolic stress, including insulin resistance, lipid metabolism dysregulation, and hepatic steatosis.